Semaglutide (Ozempic/Wegovy): Mechanism, Studies & Evidence
Complete scientific analysis of Semaglutide: GLP-1 mechanism, data from STEP, SUSTAIN and SELECT trials, FDA approval and comparison with Tirzepatide.
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Mechanism of Action
Semaglutide is a long-acting GLP-1 receptor agonist (glucagon-like peptide-1) with 94% homology to human GLP-1. Studies demonstrate it stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic appetite control centers via GLP-1R receptors in the CNS.
Data based on available scientific literature. Protocol individualization depends on qualified professional assessment.
Applications Described in the Literature
- ✓SUSTAIN trials: glycemic control in type 2 diabetes with HbA1c reduction
- ✓STEP trials: weight loss in overweight/obese adults — results up to 15% weight reduction
- ✓SELECT trial: reduction of major cardiovascular events in obese patients without diabetes
- ✓Research in non-alcoholic fatty liver disease (MAFLD/NASH)
- ✓Exploratory studies in neuroprotection and Alzheimer's disease
Relevant Studies
STEP 1: Semaglutide 2.4 mg for Chronic Weight Management
2021 · PMID: 33567185
SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 · PMID: 37551135
SUSTAIN-6: Cardiovascular outcomes with semaglutide in type 2 diabetes
2016 · PMID: 27633186
Premium
✓ DesbloqueadoProtocols Described in the Literature
Protocols described in the STEP clinical trials use progressive titration to minimize gastrointestinal side effects. Dose escalation is performed at 4-week intervals, starting from lower doses. The oral formulation was studied in daily doses, while the subcutaneous formulation is weekly. Combination studies with bariatric surgery and very low-calorie diets are documented.
Dose Ranges Observed in Studies
- ◆Subcutaneous formulation for obesity: STEP trials used 2.4 mg/week as target dose
- ◆Titration in trials: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg at 4-week intervals
- ◆Oral formulation (Rybelsus): studies used 3 mg, 7 mg and 14 mg/day
- ◆Subcutaneous formulation for diabetes (Ozempic): approved at 0.5 mg and 1.0 mg/week
Effects Timeline (Literature)
STEP studies document progressive weight loss over 68 weeks. Greatest rate of loss in the first 20 weeks. Plateau observed between 60–68 weeks. Glycemic control (HbA1c) documented from 4–8 weeks. Cardiovascular event reduction demonstrated in a 5-year study (LEADER/SELECT).
Documented Associations
- ↗Tirzepatide: directly compared in SURMOUNT-5 trial, with tirzepatide demonstrating greater weight loss
- ↗Metformin: documented combination in diabetes studies with additive HbA1c benefit
- ↗SGLT-2 inhibitors: plausibility of complementary cardiovascular and renal benefit
- ↗Nutritional intervention: STEP studies included concurrent caloric restriction (500 kcal/day)
Monitoring Described in Studies
- ⊕HbA1c: primary efficacy marker in diabetes studies, assessed every 3 months
- ⊕Body weight and waist circumference: assessed monthly in STEP trials
- ⊕Heart rate: small increase (~3 bpm) documented in studies
- ⊕Pancreatic amylase and lipase: monitoring recommended in safety studies
- ⊕Fundoscopy: retinopathy assessment in studies in diabetic patients
Clinical Observations from Studies
- ℹFDA and ANVISA approved drug with extensive human clinical evidence base
- ℹWeight regain upon discontinuation: studies demonstrate recovery of ~2/3 of lost weight within 1 year
- ℹGastrointestinal effects (nausea, vomiting): most prevalent in the first 8–12 weeks of titration
- ℹMedullary thyroid cancer risk: signal identified in animal models, contraindicated in family history
All information above is exclusively educational, based on scientific literature. It does not constitute medical prescription. Individualization of any protocol requires evaluation by a qualified healthcare professional.
Frequently Asked Questions
Is Semaglutide the same as Ozempic?▼
Yes. Ozempic® and Wegovy® contain the same active ingredient (semaglutide), approved for different indications: Ozempic for T2D and Wegovy for weight management (2.4 mg/week).
What is the difference between Semaglutide and Tirzepatide?▼
Semaglutide is a selective GLP-1 agonist, while Tirzepatide acts on GLP-1 + GIP. SURPASS-2 showed greater weight and HbA1c reduction with Tirzepatide.
⚠️ Medical Disclaimer: The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.